Ipilimumab, a monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), has been explored in combination with other immune checkpoint inhibitors like nivolumab for the treatment of lung cancer, but its use as monotherapy is less common. The gene discussed is CTLA4; the disease is lung cancer.